Quantity of qualified individuals: CDEC talked about the uncertainty in the number of clients with reasonably severe to extreme hemophilia B in Canada eligible for etranacogene dezaparvovec. Scientific authorities consulted by CADTH indicated that some sufferers who are labeled as having gentle or average ailment might have a significant bleeding https://hemgenix95050.blogvivi.com/36654317/hemgenix-an-overview